Advertisement

Topics

Johnson Matthey Plc Company Profile

19:59 EDT 24th June 2018 | BioPortfolio

Johnson Matthey is a speciality chemicals company and a world leader in advanced materials technology. The group focuses on its core skills in catalysts, precious metals and fine chemicals, developing products that enhance the quality of life for millions around the world.Since its foundation as a precious metals assayer in 1817, Johnson Matthey has continued to develop new technology, demonstrating its ability to maintain world leadership by adapting constantly to the ever-changing needs of customers. Today the company employs around 7,700 people in over 30 countries across the globe and its principal activities reflect its core skills.

Location

40-42 Hatton Garden
London
London
EC1N 8EE
United Kingdom

Contact

Phone: 44 (0)20 7269 8400
Fax: 44 (0)20 7269 8433
Email: webforms@magus.co.uk


News Articles [758 Associated News Articles listed on BioPortfolio]

#jobs #lifescience Johnson Matthey: RESEARCH SCIENTISTS – Permanent and Fixed Term Contracts

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Johnson Matthey: RESEARCH SCIENTISTS – Permanent and Fixed Term Contracts ....

Johnson Matthey exits manufacturing site in Pennsylvania, cuts 80 jobs

Inadequate small batch capabilities are behind Johnson Mattheyâs decision to close its bulk manufacturing facility in Pennsylvania, US.

Johnson Matthey boosted by Berenberg upgrade to ‘buy’, thinks battery opportunity in "for free”

Berenberg's analysts said Johnson Matthey’s “recently announced share gains in European autocatalysts should facilitate a return to high-single-digit earnings growth, and we believe it is more tha...

Johnson Matthey sends catalysts to Japan under DSKH deal

Johnson Matthey will extend its catalysts services to Japan, under a distribution agreement signed with DKSH.

DKSH signs distribution agreement with Johnson Matthey in Japan

DKSH, a Market Expansion Services provider with a focus on Asia, and Johnson Matthey, a science specialist looking to enable cleaner air, improved health and more efficient use of natural resources, h...

Johnson Matthey sends catalysts to Japan under DKSH deal

Johnson Matthey will extend its catalysts services to Japan, under a distribution agreement signed with DKSH.

DKSH signs exclusive distribution agreement with Johnson Matthey in Japan

DKSH’s Business Unit Performance Materials has been selected as the exclusive distributor in Japan for Johnson Matthey’s broad spectrum of biocatalysts, advanced homogeneous and heterogeneous cata...

Johnson Matthey to take £50mln hit as it settles engine lawsuit

A car parts maker took Johnson and another supplier to court in November, with the dispute relating to a coating substrate supplied by Johnson for use in engine emission after treatment systems

PubMed Articles [57 Associated PubMed Articles listed on BioPortfolio]

Nursing care of a boy seriously infected with Steven-Johnson syndrome after treatment with azithromycin: A case report and literature review.

Stevens-Johnson syndrome (SJS) is an acute blistering disease of the skin and mucous membranes. SJS in children is not common but potentially serious disease. But the epidemiology of SJS in China is n...

Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening cutaneous reactions, typically to drugs or infection. The incidence and outcomes of these conditions in childre...

Life-threatening dermatoses: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Impact on the Spanish public health system (2010-2015).

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are serious mucocutaneous reactions. In Spain, the epidemiology and resulting expenses of these diseases are not well established.

Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiological and clinical outcomes analysis in public hospitals.

Adverse drug reactions are harmful and involuntary responses to drugs that occur at doses normally used for a given condition. Among them are Stevens-Johnson syndrome and toxic epidermal necrolysis, b...

Stevens-Johnson syndrome and toxic epidermal necrolysis-like cutaneous presentation of chikungunya fever: A case series.

Chikungunya fever is a benign, self-limiting, acute viral illness. An epidemic occurred in New Delhi, India, in August and September 2016. We observed many cases with atypical cutaneous features mimic...

Clinical Trials [48 Associated Clinical Trials listed on BioPortfolio]

Stevens-Johnson Syndrome Antimicrobial

Steven-Johnson's syndrome, or great multiform erythema, appears as a systemic disturbance, with skin involvement and mucous membranes, related to several factors, such as, viral or bacteri...

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion crit...

Extracorporeal Photopheresis Pilot Study

ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson & Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allow...

A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition

The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20 ...

A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition

The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20 ...

Companies [165 Associated Companies listed on BioPortfolio]

Macfarlan Smith

Founded in 1780, Macfarlan Smith has over 200 years of expertise in natural product extractions and chemical synthesis, specialising in opiate narcotics such as Codeine and Morphine. Over the past 2 c...

Aoxing Pharmaceutical Company

Johnson Matthey is a specialty chemicals company, publicly traded in London Stock Exchange, focused on its core skills in catalysis, precious metals, fine chemicals and process technology. Johnson Ma...

Johnson Matthey Plc

Johnson Matthey is a speciality chemicals company and a world leader in advanced materials technology. The group focuses on its core skills in catalysts, precious metals and fine chemicals, developing...

Johnson Matthey Pharma Services

We are a pharmaceutical chemistry services company providing API outsourcing solutions throughout the drug development process, from early stage discovery services to commercial manufacturing.We enabl...

Johnson and Johnson

Johnson & Johnson, employing approximately 119,000 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnso...

More Information about "Johnson Matthey Plc" on BioPortfolio

We have published hundreds of Johnson Matthey Plc news stories on BioPortfolio along with dozens of Johnson Matthey Plc Clinical Trials and PubMed Articles about Johnson Matthey Plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Johnson Matthey Plc Companies in our database. You can also find out about relevant Johnson Matthey Plc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record